Over the last few decades, doctors have done a better job at convincing their patients to stop smoking. But much of this improvement has been relegated to patients without mental illness.
Kevin M. Gray, MD
Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC
Dr. Gray has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
A large focus of my career has been on doing National Institutes of Health–sponsored research into better understanding substance use disorders in young people. So, that would include adolescents and young adults.
You’ve probably read about internet gaming disorder (IGD), and even heard about a man in Taiwan who died while continuously playing online games for 3 straight days. There’s still debate over how to classify and treat pathological gaming: Is it its own disorder, or just a symptom of another underlying mental illness?
Rehan Aziz, MD
Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Considering them less lethal than traditional cigarettes, many adolescents are turning to electronic cigarettes as a “safer” alternative to tobacco products.
Thomas Jordan, MD
Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
It’s well established that long-term, heavy alcohol use can damage the brain and can cause problems such as Wernicke-Korsakoff syndrome and alcohol-related dementia. But what about the vast majority of our patients, who drink moderately?
The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 2 CME credits.
A recent study in The Lancet appears to conclude that Vivitrol (extended release naltrexone) and Suboxone (buprenorphine/naloxone) are equally effective treatments for patients with opioid use disorders (Lee JD et al, The Lancet 2018;391(10118):309–318)—at least this is how the study has generally been reported.
John F. Kelly, PhD
Dr. Kelly is the Elizabeth R. Spallin Associate Professor of Psychiatry in Addiction Medicine, Harvard Medical School. He is also founder and director of the Recovery Research Institute, Massachusetts General Hospital.
Dr. Kelly has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Stigma is a condition that can be socially discrediting. When it comes to substance use disorders, internalized stigma can lead to feelings of shame. Often, people who suffer from addiction feel discriminated against. People also feel very bad about their behavior, and over time they get more disillusioned with themselves and their own ability to change.
Gabapentin (Neurontin) is a “novel anticonvulsant” and is FDA indicated for partial seizures and post-herpetic neuralgia. But the drug has long been heavily marketed to psychiatrists to treat a range of conditions from bipolar disorder to anxiety to alcohol withdrawal